Proven Lupus Treatment By Dr Gary Levin

Proven Lupus Treatment System

Get Instant Access

Chronic cutaneous lupus erythematosus (CCLE) comprises different clinical entities with discoid lupus erythematosus (DLE) as the most common form. In contrast to acute cutaneous LE (ACLE) and subacute cutaneous LE (SCLE), lesions are long-lasting for up to decades with occasional spontaneous remissions. Disfiguring atrophy and scarring with emotional discomfort for patients as well as an increased risk to develop into squamous cell carcinoma in long-standing DLE pose distinct medical problems (Sontheimer and Provost 1996, Patel and Werth 2002). In many cases, symptoms are restricted to the skin without major systemic inflammatory or autoimmune manifestations. This used to be undiscriminately called DLE until twenty years ago when it was clearly dissected from other forms, especially from what is now referred to as SCLE. The term DLE should nowadays be restricted to subsets of CCLE with morphologically distinct plaques irrespective of systemic involvement.

In other, rather rare cases, DLE as well as further subsets of CCLE may present as first or intercurrent manifestations of SCLE and SLE and will eventually result in systemic disease. Exact epidemiological data of the different CCLE subtypes as well as their relation to SLE and SCLE are not available partly due to the different perception over the last couple of decades and within dermatology and rheumatology. CCLE may be underestimated within rheumatological literature and in case of absent systemic manifestations not be amply diagnosed at all. CCLE lesions, especially DLE lesions are found in up to 20% of SCLE patients and may predate manifestation of systemic disease. Further support of the relation as well as distinction of DLE and SLE is provided by the finding that DLE is present in 15-30% of SLE patients at any time during the disease course and is the prominent feature in 5-10% of such patients (Kanda et al. 1996; Parodi and Rebora 1997; Tebbe et al. 1997). Classical DLE as termed at the time of first diagnosis will progress into SLE in 5-10% of cases (Parodi and Rebora 1997; Tebbe et al. 1997). Such courses may account for different criteria of diagnosing SLE and varying medical check-up among different medical specialists. Generalized DLE and DLE associated with high autoantibody titers have a higher chance to develop into systemic disease. However, the overall incidence of DLE is ten-fold higher than that of SLE. At the same time, the female to male ratio of 3:2 to 3:1 for DLE is quite distinct from 9:1 in SLE indicating separate entities. Similarly, the age of disease manifestation (20-40 years) is slightly higher in DLE than in SLE. The other CCLE subtypes show varying correlations to SLE and will be discussed below (Sontheimer and Provost 1996).

The issue of CCLE being a distinct and separate entity at the benign end of a spectrum of LE or a limited stage or concurrent manifestation within the chronological evolution of SLE has to be further evaluated. Especially, characteristic etiopathogenetic factors as well as prognostic markers for CCLE remain to be elucidated. The final diagnosis of a distinct subset of LE can only be made following case history, clinical manifestations at the skin and other organs and laboratory findings encompassing the criteria defined by the American College of Rheumatology (ACR). Alternative criteria for cutaneous lesions have been suggested by the European Academy of Dermatology and Venereology (EADV). Being more specific, however less sensitive than the ACR criteria, they have not found their way into the rheumatologic literature (Parodi and Rebora 1997).

Was this article helpful?

0 0

Post a comment